- Excellent sales momentum in 2017 with a 10.2% increase in sales, at constant exchange rates and scope of consolidation:
- €2,288 million in sales
- Up 8.8% as reported
- Strong 12.4% increase in contributive operating income before non-recurring items to €335 million, in line with the objectives set
- Fast growth in free cash flow to €164 million versus €85 million in 2016
- 2018 objectives:
- Organic growth in sales of between 8% and 9%, at constant exchange rates and scope of consolidation
- Contributive operating income before non-recurring items of between €325 million and €345 million, despite a negative currency impact anticipated at around €40 million
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux delivered another solid operating and financial performance in 2017. Thanks to a robust sales momentum and careful control of operating expenses, the Company recorded sharp increases in contributive operating income before non-recurring items, net income and free cash flow. Buoyed by these results, we head into 2018 with the ambition to sustain this dynamic while strengthening our commitment to innovation and R&D.”